Docetaxel plus prednisone for treatment of hormone refractory prostate cancer

SUN Zhong-quan,QIAN Wei-qing,SONG Jian-da

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2009.17.023

2007-01-01

Abstract:Objective To evaluate the efficacy of docetaxel plus prednisone for the treatment of hormone refractory prostate cancer (HRPC). Methods Between September 2004 and January 2007, 13 patients (mean age, 75 years; range, 69-82 years) with HRPC were treated with prednisone (5 mg bid) and docetaxel (75mg/m2, at 3-week intervals). Inclusion criteria were previous complete androgen blockade, anti-androgen withdrawal evaluation, clinical or biochemical disease progression, and at least one time second line hormone therapy failure other than anti-androgen withdrawal. The end points were changes in PSA, pain and soft tissue metastases. Results Of the 13 patients, one patient was lost for follow-up, 11 patients were evaluated for therapeutic response and 12 patients were evaluated for toxicity. PSA levels decreased by at least 50% in 6 of the 11 patients ( 54%), from 23.6 ng/ml, 515.5 ng/ml,150.0 ng/ml, 16.4 ng/ml,152.7 ng/ml, and12.3 ng/ml before treatment to 2.4 ng/ml,139.9 ng/ml, 42.3 ng/ml, 6.7 ng/ml, 67.5 ng/ml and 5.7 ng/ml after treatment, with a duration of effective response being 4 months, 3 months, 8 months, 3 months, 2 months and 2 months. Measurable foci were stable in 2 patients. Bone pain was relieved in 50% of the patients. Grade 3 myelosuppression occurred in 50% of the patients. The median follow-up duration of the 12 follow-up patients was 194 days. Five patients died, with a median survival of 36 months from the day of diagnosis of AIPCa. Conclusions Docetaxel (at 3-week intervals) plus prednisone is an effective and well-tolerated regimen for patients with HRPC.